OA10880A - Compositions comprising an hiv protease inhibitor such as vx 478 and a water soluble vitamin e compound such as vitamin e-tpgs - Google Patents

Compositions comprising an hiv protease inhibitor such as vx 478 and a water soluble vitamin e compound such as vitamin e-tpgs Download PDF

Info

Publication number
OA10880A
OA10880A OA9800171A OA9800171A OA10880A OA 10880 A OA10880 A OA 10880A OA 9800171 A OA9800171 A OA 9800171A OA 9800171 A OA9800171 A OA 9800171A OA 10880 A OA10880 A OA 10880A
Authority
OA
OAPI
Prior art keywords
tpgs
vitamin
compound
water soluble
hiv protease
Prior art date
Application number
OA9800171A
Other languages
English (en)
Inventor
Arup K Roy
Lioyd Gary Tillman
Original Assignee
Glaxo Group Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB9606372.2A external-priority patent/GB9606372D0/en
Application filed by Glaxo Group Ltd filed Critical Glaxo Group Ltd
Publication of OA10880A publication Critical patent/OA10880A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/63—Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide
    • A61K31/635—Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide having a heterocyclic ring, e.g. sulfadiazine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4858—Organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Virology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • AIDS & HIV (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
OA9800171A 1996-03-22 1998-09-18 Compositions comprising an hiv protease inhibitor such as vx 478 and a water soluble vitamin e compound such as vitamin e-tpgs OA10880A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US1389396P 1996-03-22 1996-03-22
GBGB9606372.2A GB9606372D0 (en) 1996-03-26 1996-03-26 Pharmaceutical formulations

Publications (1)

Publication Number Publication Date
OA10880A true OA10880A (en) 2001-10-11

Family

ID=26308992

Family Applications (1)

Application Number Title Priority Date Filing Date
OA9800171A OA10880A (en) 1996-03-22 1998-09-18 Compositions comprising an hiv protease inhibitor such as vx 478 and a water soluble vitamin e compound such as vitamin e-tpgs

Country Status (12)

Country Link
JP (1) JP3117726B2 (pl)
AR (1) AR006345A1 (pl)
BG (1) BG64457B1 (pl)
CO (1) CO4790151A1 (pl)
HU (1) HU228026B1 (pl)
ID (1) ID16781A (pl)
IL (1) IL126185A (pl)
MY (1) MY126358A (pl)
OA (1) OA10880A (pl)
PL (1) PL187919B1 (pl)
TW (1) TW455491B (pl)
WO (1) WO1997035587A1 (pl)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2264718C (en) * 1996-09-01 2006-05-30 Pharmos Corporation Solid coprecipitates for enhanced bioavailability of lipophilic substances
WO1998057648A1 (en) * 1997-06-16 1998-12-23 Vertex Pharmaceuticals Incorporated Methods of increasing the bioavailability of stable crystal polymorphs of a compound
US5891845A (en) * 1997-11-21 1999-04-06 Fuisz Technologies Ltd. Drug delivery systems utilizing liquid crystal structures
ES2140329B1 (es) * 1997-12-04 2000-10-16 Univ Granada Utilizacion de acido maslinico como inhibidor de proteasas para el tratamiento de la enfermedad causada por los virus de la inmunodeficiencia adquirida.
GB9812189D0 (en) * 1998-06-05 1998-08-05 Glaxo Group Ltd Methods and compositions for increasing penetration of HIV protease inhibitors
CA2432527A1 (en) * 2000-12-22 2002-07-04 Takeda Chemical Industries, Ltd. Medicinal compositions for oral use
AU2002350719A1 (en) 2002-11-29 2004-06-23 Janssen Pharmaceutica N.V. Pharmaceutical compositions comprising a basic respectively acidic drug compound, a surfactant and a physiologically tolerable water-soluble acid respectively base
EP1592760A4 (en) 2003-01-31 2009-08-12 Smithkline Beecham Corp AS FIXED DISPERSIONS, COMPOSITIONS
US20060068007A1 (en) * 2004-09-24 2006-03-30 Boehringer Ingelheim Pharmaceuticals, Inc. Class of surfactant-like materials
CN101031284A (zh) * 2004-09-30 2007-09-05 伊斯曼化学公司 使亲脂性药物增溶而无显著外排抑制作用的含有维生素e tpgs分子的药物制剂和该制剂的用途
EP1880715A1 (en) * 2006-07-19 2008-01-23 Abbott GmbH & Co. KG Pharmaceutically acceptable solubilizing composition and pharmaceutical dosage form containing same
SA109300195B1 (ar) 2008-03-28 2013-04-20 Astrazeneca Ab تركيبة صيدلانية جديدة مضادة للسرطان
ITRM20120331A1 (it) 2012-07-12 2014-01-13 Guidotti & C Spa Labor Composizioni pediatriche orali liquide contenenti nepadutant.

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1992016501A1 (en) * 1991-03-20 1992-10-01 Vertex Pharmaceuticals Incorporated Tetrahydroxyalkane derivatives as inhibitors of hiv aspartyl protease
CA2081970C (en) * 1991-11-08 1997-07-08 Joseph P. Vacca Hiv protease inhibitors useful for the treatment of aids
IS2334B (is) * 1992-09-08 2008-02-15 Vertex Pharmaceuticals Inc., (A Massachusetts Corporation) Aspartyl próteasi hemjari af nýjum flokki súlfonamíða
WO1994013629A1 (en) * 1992-12-11 1994-06-23 Vertex Pharmaceuticals Incorporated Mannitol derivatives and their use as inhibitors of aspartyl protease
US5484926A (en) * 1993-10-07 1996-01-16 Agouron Pharmaceuticals, Inc. HIV protease inhibitors
DE69334250D1 (de) * 1992-12-29 2009-01-29 Abbott Lab Verfahren und Intermediate zur Herstellung von retroviralen Proteasehemmern
AU6122994A (en) * 1993-01-15 1994-08-15 Agouron Pharmaceuticals, Inc. Hiv protease inhibitors and their preparation
WO1995012583A1 (en) * 1993-11-05 1995-05-11 Merck & Co., Inc. New quinazolines as inhibitors of hiv reverse transcriptase
IL111584A0 (en) * 1993-11-18 1995-01-24 Merck & Co Inc Prodrugs of an inhibitor of hiv protease and pharmaceutical compositions containing them
PL314984A1 (en) * 1993-12-15 1996-09-30 Merck & Co Inc Hiv protease inhibitors
ES2139195T3 (es) * 1994-03-07 2000-02-01 Vertex Pharma Derivados de sulfonamidas como inhibidores de la aspartil-proteasa.
GB9409778D0 (en) * 1994-05-16 1994-07-06 Dumex Ltd As Compositions
US5527829A (en) * 1994-05-23 1996-06-18 Agouron Pharmaceuticals, Inc. HIV protease inhibitors
JPH11505257A (ja) * 1995-05-19 1999-05-18 アボツト・ラボラトリーズ 親油性薬物の自己乳化性製剤

Also Published As

Publication number Publication date
PL187919B1 (pl) 2004-11-30
BG64457B1 (bg) 2005-03-31
AR006345A1 (es) 1999-08-25
HUP9901887A2 (hu) 1999-12-28
TW455491B (en) 2001-09-21
CO4790151A1 (es) 1999-05-31
PL328916A1 (en) 1999-03-01
ID16781A (id) 1997-11-13
JP3117726B2 (ja) 2000-12-18
BG102838A (en) 1999-09-30
WO1997035587A1 (en) 1997-10-02
MY126358A (en) 2006-09-29
HU228026B1 (en) 2012-08-28
IL126185A0 (en) 1999-05-09
HUP9901887A3 (en) 2000-02-28
IL126185A (en) 2003-05-29
JP2000500504A (ja) 2000-01-18

Similar Documents

Publication Publication Date Title
US5200192A (en) Instant oral-release capsule containing nifedipine
US20110020440A1 (en) Stable solutions of sparingly soluble actives
US6730679B1 (en) Pharmaceutical formulations
OA10880A (en) Compositions comprising an hiv protease inhibitor such as vx 478 and a water soluble vitamin e compound such as vitamin e-tpgs
US6551615B1 (en) Dexibuprofen-containing soft gelatin capsules and process for preparing the same
AU2002356421A1 (en) Dexibuprofen-containing soft gelatin capsules and process for preparing the same
AP1150A (en) Compositions comprising an HIV protease inhibitor such as Vx 478 and a water soluble vitamin E compound such as vitamin E-TPGS.
KR100472581B1 (ko) Vx478과같은hiv프로테아제억제제및비타민e-tpgs와같은수용성비타민e화합물을포함하는조성물
US7632853B2 (en) Soluble, stable and concentrated pharmaceutical composition compromising ritonavir and process for preparing thereof
US20060141028A1 (en) Cyclosporin formulations
AU2010338249B2 (en) Oral liquid pharmaceutical composition of nifedipine
UA67723C2 (en) Pharmaceutical formulations for peroral administration and method for its preparation
US20060217320A1 (en) Soft gel formulations for saquinavir
TR201510144A2 (tr) Yeni̇ oral çözelti̇ formülasyonu